High-risk cervical human papillomavirus infection
Conditions
Interventions
Group 1:Shuang Yinjie
Sponsors
Changshu City Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) HPV high-risk DNA test was positive; (2) Women between the ages of 20 and 60 who are married or have a sexual history; (3) no immune system diseases and major organ diseases; (4) Those who can persist in completing treatment; (5) Treatment without other anti-HPV drugs during the study period; (6) Voluntarily participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Pregnant, lactating women or within 6 months after delivery; (2) Cervical pathology examination complicated with cervical intraepithelial neoplasia (including CIN I-III grade); (3) cervical cancer; (4) have a variety of vaginitis, or acute, subacute pelvic inflammation; (5) Allergic constitution, or known to be allergic to E. coli expression proteins or allergic to other components of the tested drug; (6) Complications such as chronic diseases of internal medicine and immune system diseases, neurological diseases, and other conditions that researchers believe that patients should not be included in this trial; (7) Have a history of serious drug abuse or alcohol abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HPV negative conversion rate and overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events during and 3 months after medication;Solicited adverse events: Adverse events that have been documented in the specification;Unsolicited adverse events: other adverse events; | — |
Countries
China
Contacts
Public ContactZhao Na
Changshu City Hospital of Traditional Chinese Medicine
Outcome results
None listed